{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-25-000006","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.852055+00:00","generated_at":"2026-05-24T23:52:10.599607+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Werewolf Therapeutics reports Q4 2024 net loss of $20.4M; cash runway through Q2 2026","bullets":["Cash and cash equivalents $111.0M at Dec 31, 2024; sufficient to fund operations through Q2 2026.","Net loss $20.4M in Q4 2024 vs $12.0M in Q4 2023; full year net loss $70.5M vs $37.4M.","Collaboration revenue $0 in Q4 2024 as Jazz obligation completed; full year $1.9M vs $19.9M.","WTX-124 monotherapy melanoma expansion arm expected fully enrolled H1 2025; combination arm by end of 2025.","Plan to meet with FDA in H2 2025 for registrational pathways; interim data expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-25-000006","json":"https://secwatch.observer/filing/0001785530-25-000006.json","markdown":"https://secwatch.observer/filing/0001785530-25-000006.md","text":"https://secwatch.observer/filing/0001785530-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/0001785530-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553025000006/howl-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:52:10.599607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}